Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 07, 2015 4:26 AM ET

Healthcare Equipment and Supplies

Company Overview of Ventana Medical Systems, Inc.

Company Overview

Ventana Medical Systems Inc. develops, manufactures, and markets instrument-reagent systems that automate slide staining. Its clinical systems are used in anatomical pathology labs in analyzing human tissue to assist in diagnosing and treating cancer and infectious diseases. Ventana’s drug-discovery systems are used by pharmaceutical and biotech companies to increase the discovery of new drug targets and to evaluate the safety of new compounds. It also markets consumable products, including reagents and other accessories, and serves hospital-based anatomical pathology labs, independent reference labs, government labs, medical research centers, and resellers serving these entities. Ventana Me...

1910 East Innovation Park Drive

Tucson, AZ 85755

United States

Founded in 1985

952 Employees

Phone:

520-887-2155

Fax:

520-229-4207

Key Executives for Ventana Medical Systems, Inc.

Chief Executive Officer and Director
Age: 64
Founder, Chairman Emeritus, Chief Scientific Officer and Chief Medical Officer
Age: 68
Chief Financial Officer and Senior Vice President
Age: 48
Chief Operating Officer
Age: 53
Senior Vice President and General Counsel
Age: 60
Compensation as of Fiscal Year 2014.

Ventana Medical Systems, Inc. Key Developments

Ventana Medical Systems, Inc. Enters into Master Collaboration Agreement with Astellas Pharma Inc

Ventana Medical Systems, Inc. announced it has entered into master collaboration agreement with Astellas Pharma Inc. to develop novel automated tissue diagnostics in support of therapeutic compounds in development. Initial projects related to this agreement will support early-stage clinical trials for the Astellas therapeutic compound ASP5878, a novel small-molecule fibroblast growth factor receptor (FGFR) inhibitor which has been shown to block the kinase activities of FGFR1, FGFR2, FGFR3 and FGFR4. Ventana will develop, in parallel, an immunohistochemistry (IHC) test identifying FGF19 in certain solid tumors.

Ventana Medical Systems, Inc. Announces Collaboration to Develop Companion Diagnostics for ImmunoGen, Inc.'s Targeted Anticancer Agents

Ventana Medical Systems, Inc. announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha (FRa, also known as folate receptor 1, or FOL1) that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate (ADC). Cancers that highly express FRa include epithelial ovarian cancer, endometrial cancer, and types of non-small cell lung cancers (NSCLC). The goal of the collaboration is to leverage Ventana's expertise in companion diagnostic development, from prototyping through regulatory approval and commercialization, to identify specific patient populations for ImmunoGen's bio-target directed therapies. This pharma collaboration is one of dozens currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tools that help identify those individuals who are most likely to benefit from specific treatments. In addition to ImmunoGen, Ventana has announced collaborations with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more.

Ventana Medical Systems, Inc. Enters into Agreement with Quintiles, Inc. to Offer College of American Pathology-Standard Companion Diagnostic Testing Services in China

Ventana Medical Systems, Inc. announced a new agreement with Quintiles, Inc. to offer College of American Pathology (CAP)-standard companion diagnostic testing services in China for pharmaceutical and biotech companies conducting early phase clinical trials. Early phase clinical trial testing according to the rigorous CAP standards set by Ventana is available now.

Similar Private Companies By Industry

Company Name Region
Synapse Biomedical, Inc. United States
Respiratory Technologies, Inc. United States
Cyberkinetics Neurotechnology Systems Inc. United States
K-D Medical, Inc. United States
Fisher Scientific Worldwide Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ventana Medical Systems, Inc., please visit www.ventana.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.